Organogenesis Holdings Inc. (ORGO) P/E Ratio History
UndervaluedTrading at 16.2x vs 5Y avg 36.7x · 27th percentile · Below historical baseline · Data 2020–2025
Loading P/E history...
P/E Ratio Analysis
As of June 29, 2026, Organogenesis Holdings Inc. (ORGO) trades at a price-to-earnings ratio of 16.2x, with a stock price of $2.43 and trailing twelve-month earnings per share of $-0.00.
The current P/E is 56% below its 5-year average of 36.7x. Over the past five years, ORGO's P/E has ranged from a low of 7.1x to a high of 111.1x, placing the current valuation at the 27th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, ORGO trades at a 30% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, ORGO trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ORGO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ORGO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ORGO P/E vs Peers
Therapy-focused branded biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $584M | 12.3Lowest | - | +14% | |
| $1B | 19.4 | 0.58Best | -35% | |
| $59M | 14.0 | - | +125%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ORGO Historical P/E Data (2020–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $5.18 | $0.11 | 45.5x | +24% |
| FY2024 Q1 | Mar 31 2024 | $2.84 | $0.04 | 65.3x | +78% |
| FY2023 Q4 | Dec 31 2023 | $4.09 | $0.04 | 111.1x | +203% |
| FY2023 Q3 | Sep 30 2023 | $3.18 | $0.10 | 32.5x | -12% |
| FY2023 Q2 | Jun 30 2023 | $3.32 | $0.08 | 43.8x | +19% |
| FY2023 Q1 | Mar 31 2023 | $2.13 | $0.10 | 20.9x | -43% |
| FY2022 Q4 | Dec 31 2022 | $2.69 | $0.13 | 21.5x | -41% |
| FY2022 Q3 | Sep 30 2022 | $3.24 | $0.46 | 7.1x | -81% |
| FY2022 Q2 | - | $4.88 | $0.55 | 8.9x | -76% |
| FY2022 Q1 | - | $7.62 | $0.63 | 12.1x | -67% |
| FY2021 Q4 | Dec 31 2021 | $9.24 | $0.70 | 13.2x | -64% |
| FY2021 Q3 | - | $14.24 | $0.46 | 31.0x | -16% |
| FY2021 Q2 | Jun 30 2021 | $16.62 | $0.56 | 29.7x | -19% |
| FY2021 Q1 | Mar 31 2021 | $18.22 | $0.36 | 50.5x | +38% |
| FY2020 Q4 | - | $7.53 | $0.13 | 57.6x | +57% |
Average P/E for displayed period: 36.7x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ORGO — Frequently Asked Questions
Quick answers to the most common questions about buying ORGO stock.
What is ORGO's P/E ratio?
Organogenesis Holdings Inc. (ORGO) trailing twelve-month P/E ratio is 16.2x, based on TTM diluted EPS of $-0.00. The 5-year average P/E is 36.7x and the historical range spans 7.1x to 111.1x.
Is ORGO stock overvalued or undervalued?
ORGO trades at 16.2x P/E, below its 5-year average of 36.7x. At the 27th percentile of its historical range (7.1x–111.1x), the stock is priced at a discount to its own history.
Is ORGO stock expensive?
No, ORGO is not expensive on a historical basis. The current P/E of 16.2x is below the 5-year average of 36.7x and sits at the 27th percentile of its valuation range.
What is ORGO's historical P/E range?
Over the past 5 years, ORGO's P/E ratio has ranged from 7.1x to 111.1x, with a median of 31.0x and an average of 36.7x. The current P/E of 16.2x places the stock at the 27th percentile of this range. Full historical data spans 2020–2025.
How does ORGO's P/E compare to the S&P 500?
ORGO trades at 16.2x P/E versus the S&P 500 median of 25.3x. The 36% discount to the market suggests lower growth expectations or perceived higher risk.
How does ORGO's valuation compare to Healthcare peers?
Organogenesis Holdings Inc. P/E of 16.2x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ORGO's PEG ratio?
ORGO PEG ratio is N/A, based on a P/E of 16.2x and EPS growth of 1600.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ORGO's earnings yield?
ORGO earnings yield is 6.17%, the inverse of its 16.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.